Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15)

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 5, 2017, Pages 1386-1395

  Pfaller, Michael A ^a,b   Bassetti, Matteo ^c   Duncan, Leonard R ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c S Maria Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER; DRUG ACTIVITY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; KLEBSIELLA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIC50; MIC90; NONHUMAN; PHENOTYPE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; ISRAEL; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; INTRAABDOMINAL INFECTIONS; ISRAEL; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TURKEY; URINARY TRACT INFECTIONS;

EID: 85019081486     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx009     Document Type: Article

References (27)

1. Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208
2. Magill SS, Edwards JR, Beldavs ZG et al. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA 2014; 312: 1438-46
3. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9
4. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22 Suppl 2: S89-94
5. WisplinghoffH, BischoffT, Tallent SMet al. Nosocomial bloodstreaminfections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17
6. Kollef MH, Golan Y, Micek ST et al. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections-proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 2011; 53 Suppl 2: S33-55
7. Maragakis LL, Perl TM. How can we stem the rising tide of multidrugresistant gram-negative bacilli? Infect Control Hosp Epidemiol 2010; 31: 338-40
8. Opal SM, Calandra T. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA 2009; 302: 2367-8
9. Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 2012; 67: 1-3
10. ECDC. Antimicrobial Resistance Surveillance Report Europe 2013. 2014. http://ecdc. europa. eu/en/publications/Publications/antimicrobial-resistancesurveillance-europe-2013. pdf
11. CDC. National and State Healthcare-Associated Infections Progress Report. 2013. http://www. cdc. gov/HAI/pdfs/progress-report/hai-progress-re port-2015. pdf
12. BoucherHW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12
13. Zhang D, Micek ST, KollefMH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit CareMed 2015; 43: 2133-40
14. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-b-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-94
15. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11
16. Perez F, Villegas MV. The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. Curr Opin Infect Dis 2015; 28: 375-83
17. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation b-lactam/b-lactamase inhibitor combinations. Clin Infect Dis 2016; 63: 234-41
18. Farrell DJ, Flamm RK, Sader HS et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U. S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57: 6305-10
19. Farrell DJ, Sader HS, Flamm RK et al. Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European Medical Centres (2012). Int J Antimicrob Agents 2014; 43: 533-9
20. Sader HS, Farrell DJ, Castanheira M et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). J Antimicrob Chemother 2014; 69: 2713-22
21. Sader HS, Farrell DJ, Flamm RK et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intraabdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69: 266-77
22. Sader HS, Rhomberg PR, Farrell DJ et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011; 55: 2390-4
23. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard Tenth Edition-M07-A10. CLSI, Wayne, PA, USA, 2015
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-sixth Informational Supplement M100-S26. CLSI, Wayne, PA, USA, 2016
25. EUCAST (2016). Breakpoint tables for interpretation ofMICs and zone diameters. Version 6. 0, January 2016. http://www. eucast. org/clinical_breakpoints/
26. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81
27. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-31